USOR 21318 - STAR: PH1/3 Biomarker unresectable stg3 NSCLC

A Phase I−III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, with Locally Advanced, Unresectable, Stage III Non−Small Cell Lung Cancer

Disease Types: Lung - Non-Small Cell Lung, STAR: Selected Trials Available for Accelerated Four Week Rollout

Available at: Arlington Heights, Niles